BioCryst Appoints Dr. Donald Fong Chief Medical Officer
BioCryst Pharmaceuticals (Nasdaq: BCRX) has appointed Dr. Donald S. Fong as its new chief medical officer, effective immediately. Dr. Fong, who joined BioCryst in April 2024 as vice president of the ophthalmology therapeutic area, brings over 25 years of clinical experience in leading clinical trials and drug development. His appointment strengthens BioCryst's leadership team as they advance their pipeline of novel therapies, including programs for Netherton syndrome and diabetic macular edema.
Dr. Fong's extensive background includes serving as vice president of ophthalmology clinical development at Annexon Biosciences, founding the clinical trials division at Kaiser Permanente Southern California, and advising numerous FDA committees. His expertise aligns with BioCryst's focus on developing potential life-changing therapies for diseases with significant unmet needs.
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha nominato Dr. Donald S. Fong come nuovo direttore medico, con effetto immediato. Il Dr. Fong, che è entrato in BioCryst nell'aprile 2024 come vicepresidente dell'area terapeutica oftalmologica, porta con sé oltre 25 anni di esperienza clinica nella conduzione di studi clinici e nello sviluppo di farmaci. La sua nomina rafforza il team di leadership di BioCryst mentre avanzano nel loro pipeline di nuove terapie, inclusi programmi per la sindrome di Netherton e l'edema maculare diabetico.
Il vasto background del Dr. Fong include ruoli come vicepresidente dello sviluppo clinico oftalmologico presso Annexon Biosciences, la fondazione della divisione studi clinici presso Kaiser Permanente Southern California, e la consulenza a numerosi comitati della FDA. La sua esperienza è allineata con l'obiettivo di BioCryst di sviluppare terapie potenzialmente in grado di cambiare la vita per malattie con bisogni insoddisfatti significativi.
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha nombrado al Dr. Donald S. Fong como su nuevo director médico, con efecto inmediato. El Dr. Fong, quien se unió a BioCryst en abril de 2024 como vicepresidente del área terapéutica de oftalmología, aporta más de 25 años de experiencia clínica en la conducción de ensayos clínicos y desarrollo de fármacos. Su nombramiento fortalece al equipo directivo de BioCryst a medida que avanzan en su pipeline de nuevas terapias, incluidos programas para el síndrome de Netherton y el edema macular diabético.
El amplio trasfondo del Dr. Fong incluye haber sido vicepresidente de desarrollo clínico en oftalmología en Annexon Biosciences, fundador de la división de ensayos clínicos en Kaiser Permanente Southern California, y asesor de numerosos comités de la FDA. Su experiencia está alineada con el enfoque de BioCryst en desarrollar terapias potencialmente transformadoras para enfermedades con necesidades no satisfechas significativas.
BioCryst Pharmaceuticals(Nasdaq: BCRX)가 Dr. Donald S. Fong을 새로운 최고 의료 책임자로 즉시 임명했습니다. Dr. Fong은 2024년 4월에 생리학 치료 영역의 부사장으로 BioCryst에 합류하였으며, 25년 이상의 임상 경험을 가지고 있어 임상 시험과 약물 개발을 이끌어왔습니다. 그의 임명은 BioCryst의 리더십 팀을 강화하여 네더턴 증후군과 당뇨병성 황반부종을 위한 프로그램을 포함한 새로운 치료제 개발을 진전시킵니다.
Dr. Fong의 광범위한 배경은 Annexon Biosciences의 안과 임상 개발 부사장으로 근무한 경험, Kaiser Permanente Southern California에서 임상 시험 부서를 설립한 경험, 여러 FDA 위원회에 자문한 경험을 포함합니다. 그의 전문 지식은 BioCryst가 중대한 unmet needs에 대한 잠재적으로 생명을 바꿀 수 있는 치료제를 개발하는 데 초점을 맞추고 있는 것과 일치합니다.
BioCryst Pharmaceuticals (Nasdaq: BCRX) a nommé Dr. Donald S. Fong en tant que nouveau directeur médical, avec effet immédiat. Le Dr Fong, qui a rejoint BioCryst en avril 2024 en tant que vice-président du domaine thérapeutique en ophtalmologie, apporte plus de 25 ans d'expérience clinique dans la conduite d'essais cliniques et le développement de médicaments. Sa nomination renforce l'équipe de direction de BioCryst alors qu'ils avancent dans leur portefeuille de nouvelles thérapies, y compris des programmes pour le syndrome de Netherton et l'œdème maculaire diabétique.
Le parcours riche du Dr Fong comprend le poste de vice-président du développement clinique en ophtalmologie chez Annexon Biosciences, la fondation de la division des essais cliniques chez Kaiser Permanente Southern California, et le conseil à de nombreux comités de la FDA. Son expertise est en adéquation avec l'objectif de BioCryst de développer des thérapies potentiellement révolutionnaires pour les maladies présentant des besoins non satisfaits importants.
BioCryst Pharmaceuticals (Nasdaq: BCRX) hat Dr. Donald S. Fong als neuen Chief Medical Officer ernannt, mit sofortiger Wirkung. Dr. Fong, der im April 2024 als Vizepräsident im Bereich der Ophthalmologie zu BioCryst gekommen ist, bringt über 25 Jahre klinische Erfahrung in der Leitung von klinischen Studien und der Arzneimittelentwicklung mit. Seine Ernennung stärkt das Führungsteam von BioCryst, während sie ihre Pipeline innovativer Therapien vorantreiben, einschließlich Programmen für das Netherton-Syndrom und diabetisches Makulaödem.
Dr. Fongs umfangreiche Erfahrung umfasst die Tätigkeit als Vizepräsident für ophthalmologische klinische Entwicklung bei Annexon Biosciences, die Gründung der klinischen Studienabteilung bei Kaiser Permanente Southern California und die Beratung zahlreicher FDA-Ausschüsse. Seine Expertise passt zu BioCrysts Fokus auf die Entwicklung potenziell lebensverändernder Therapien für Erkrankungen mit erheblichen unerfüllten Bedürfnissen.
- Appointment of experienced Chief Medical Officer with over 25 years in clinical trials and drug development
- Strengthening of leadership team with addition of another physician
- Advancement of pipeline therapies for Netherton syndrome and diabetic macular edema
- Dr. Fong's expertise in ophthalmology aligns with BioCryst's diabetic macular edema program
- None.
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Donald S. Fong, MD, MPH, has been appointed as the company’s new chief medical officer, effective immediately.
Dr. Fong joins Dr. Helen Thackray, the company’s chief research and development officer, and Dr. Bill Sheridan, the company’s chief development officer, as physicians on the company’s leadership team.
“We continue to advance our pipeline of novel therapies to treat diseases with significant unmet needs, including programs in Netherton syndrome and diabetic macular edema that we expect will enter the clinic this year and next year, respectively. Donald’s experience leading clinical research programs for various diseases, coupled with his many years of experience and thought leadership as an ophthalmologist, make him an excellent leader for our global medical team as we continue to focus on bringing potential life-changing therapies to patients who need them,” Thackray said.
Dr. Fong joined BioCryst in April 2024 as vice president of the ophthalmology therapeutic area, where he has overseen clinical development of avoralstat, the company’s investigational plasma kallikrein inhibitor for the treatment of diabetic macular edema. He has more than 25 years of clinical experience leading clinical trials, drug development and healthcare organizations in both clinical and industry roles.
Prior to joining BioCryst, Dr. Fong served as vice president of ophthalmology clinical development at Annexon Biosciences, where he advanced the company’s asset to phase 3 trials in geographic atrophy. Prior to his time at Annexon, Dr. Fong founded the clinical trials division at Kaiser Permanente Southern California (KPSC) that oversaw trials for all medical and surgical specialties and advanced the company’s oncology group to become a leading national site. He also created and led KP’s tele-ophthalmology/telemedicine program and is a clinical professor at the KP School of Medicine. Dr. Fong has been an advisor to numerous U.S. Food and Drug Administration (FDA) advisory committees, in addition to serving as chair of the FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee. Dr. Fong received his BA from Pomona College, his MD from UT Health San Antonio and his MPH from the Harvard School of Public Health.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
FAQ
Who is the new Chief Medical Officer of BioCryst Pharmaceuticals (BCRX)?
What experience does Dr. Donald Fong bring to BioCryst (BCRX)?
What are the key pipeline programs BioCryst (BCRX) is advancing?
What was Dr. Fong's role at BioCryst (BCRX) before becoming Chief Medical Officer?
